aluates Reports

$ 0.0

Automative

Global Anti-Parkinson Drugs Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-16F6021

Global Anti Parkinson Drugs Market Insights Forecast to 2028

BUY CHAPTERS

Global Anti-Parkinson Drugs Market Research Report 2025

Code: QYRE-Auto-16F6021

Report

July 2025

Pages:81

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

AbbVie

Mylan Laboratories

Valeant Pharmaceuticals

Novartis

GlaxoSmithKline PLC

Zambon Pharmaceuticals

Pfizer Inc

Hoffmann La Roche

Merck

Orion Pharma

UCB

Teva Pharmaceutical Industries Ltd

Vertical Pharmaceuticals LLC

ACADIA Pharmaceuticals Inc.

Anti-Parkinson Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Anti-Parkinson Drugs Market

The global market for Anti-Parkinson Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Anti-Parkinson Drugs are drugs used to treat Parkinson"s disease.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Anti-Parkinson Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Parkinson Drugs.

The Anti-Parkinson Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-Parkinson Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Anti-Parkinson Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Anti-Parkinson Drugs Market Report

Report Metric	Details
Report Name	Anti-Parkinson Drugs Market
CAGR	5%
Segment by Type	Dopaminergic Dopamine Agonists Enzyme Inhibitors Others
Segment by Application	Hospital Pharmacy Retail Pharmacy Online Stores
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AbbVie, Mylan Laboratories, Valeant Pharmaceuticals, Novartis, GlaxoSmithKline, Zambon Pharmaceuticals, Pfizer, Inc., Hoffmann-La Roche, Merck & Co., Orion Pharma, UCB, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Parkinson Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Anti-Parkinson Drugs Market report?

Ans: The main players in the Anti-Parkinson Drugs Market are AbbVie, Mylan Laboratories, Valeant Pharmaceuticals, Novartis, GlaxoSmithKline, Zambon Pharmaceuticals, Pfizer, Inc., Hoffmann-La Roche, Merck & Co., Orion Pharma, UCB, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc.

What are the Application segmentation covered in the Anti-Parkinson Drugs Market report?

Ans: The Applications covered in the Anti-Parkinson Drugs Market report are Hospital Pharmacy, Retail Pharmacy, Online Stores

What are the Type segmentation covered in the Anti-Parkinson Drugs Market report?

Ans: The Types covered in the Anti-Parkinson Drugs Market report are Dopaminergic, Dopamine Agonists, Enzyme Inhibitors, Others

Recommended Reports

Neurological Drug Markets

Pharmaceutical Testing & Validation

Therapeutic Drug Markets

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Dopaminergic

1.2.3 Dopamine Agonists

1.2.4 Enzyme Inhibitors

1.2.5 Others

1.3 Market by Application

1.3.1 Global Anti-Parkinson Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Online Stores

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Anti-Parkinson Drugs Market Perspective (2020-2031)

2.2 Global Anti-Parkinson Drugs Growth Trends by Region

2.2.1 Global Anti-Parkinson Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Anti-Parkinson Drugs Historic Market Size by Region (2020-2025)

2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Region (2026-2031)

2.3 Anti-Parkinson Drugs Market Dynamics

2.3.1 Anti-Parkinson Drugs Industry Trends

2.3.2 Anti-Parkinson Drugs Market Drivers

2.3.3 Anti-Parkinson Drugs Market Challenges

2.3.4 Anti-Parkinson Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Anti-Parkinson Drugs Players by Revenue

3.1.1 Global Top Anti-Parkinson Drugs Players by Revenue (2020-2025)

3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Anti-Parkinson Drugs Revenue

3.4 Global Anti-Parkinson Drugs Market Concentration Ratio

3.4.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2024

3.5 Global Key Players of Anti-Parkinson Drugs Head office and Area Served

3.6 Global Key Players of Anti-Parkinson Drugs, Product and Application

3.7 Global Key Players of Anti-Parkinson Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Anti-Parkinson Drugs Breakdown Data by Type

4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2020-2025)

4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2026-2031)

5 Anti-Parkinson Drugs Breakdown Data by Application

5.1 Global Anti-Parkinson Drugs Historic Market Size by Application (2020-2025)

5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Anti-Parkinson Drugs Market Size (2020-2031)

6.2 North America Anti-Parkinson Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Anti-Parkinson Drugs Market Size by Country (2020-2025)

6.4 North America Anti-Parkinson Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Anti-Parkinson Drugs Market Size (2020-2031)

7.2 Europe Anti-Parkinson Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Anti-Parkinson Drugs Market Size by Country (2020-2025)

7.4 Europe Anti-Parkinson Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Anti-Parkinson Drugs Market Size (2020-2031)

8.2 Asia-Pacific Anti-Parkinson Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Anti-Parkinson Drugs Market Size (2020-2031)

9.2 Latin America Anti-Parkinson Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Anti-Parkinson Drugs Market Size by Country (2020-2025)

9.4 Latin America Anti-Parkinson Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Anti-Parkinson Drugs Market Size (2020-2031)

10.2 Middle East & Africa Anti-Parkinson Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AbbVie

11.1.1 AbbVie Company Details

11.1.2 AbbVie Business Overview

11.1.3 AbbVie Anti-Parkinson Drugs Introduction

11.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.1.5 AbbVie Recent Development

11.2 Mylan Laboratories

11.2.1 Mylan Laboratories Company Details

11.2.2 Mylan Laboratories Business Overview

11.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction

11.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.2.5 Mylan Laboratories Recent Development

11.3 Valeant Pharmaceuticals

11.3.1 Valeant Pharmaceuticals Company Details

11.3.2 Valeant Pharmaceuticals Business Overview

11.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction

11.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.3.5 Valeant Pharmaceuticals Recent Development

11.4 Novartis

11.4.1 Novartis Company Details

11.4.2 Novartis Business Overview

11.4.3 Novartis Anti-Parkinson Drugs Introduction

11.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.4.5 Novartis Recent Development

11.5 GlaxoSmithKline

11.5.1 GlaxoSmithKline Company Details

11.5.2 GlaxoSmithKline Business Overview

11.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction

11.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.5.5 GlaxoSmithKline Recent Development

11.6 Zambon Pharmaceuticals

11.6.1 Zambon Pharmaceuticals Company Details

11.6.2 Zambon Pharmaceuticals Business Overview

11.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction

11.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.6.5 Zambon Pharmaceuticals Recent Development

11.7 Pfizer, Inc.

11.7.1 Pfizer, Inc. Company Details

11.7.2 Pfizer, Inc. Business Overview

11.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction

11.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.7.5 Pfizer, Inc. Recent Development

11.8 Hoffmann-La Roche

11.8.1 Hoffmann-La Roche Company Details

11.8.2 Hoffmann-La Roche Business Overview

11.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction

11.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.8.5 Hoffmann-La Roche Recent Development

11.9 Merck & Co.

11.9.1 Merck & Co. Company Details

11.9.2 Merck & Co. Business Overview

11.9.3 Merck & Co. Anti-Parkinson Drugs Introduction

11.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.9.5 Merck & Co. Recent Development

11.10 Orion Pharma

11.10.1 Orion Pharma Company Details

11.10.2 Orion Pharma Business Overview

11.10.3 Orion Pharma Anti-Parkinson Drugs Introduction

11.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.10.5 Orion Pharma Recent Development

11.11 UCB

11.11.1 UCB Company Details

11.11.2 UCB Business Overview

11.11.3 UCB Anti-Parkinson Drugs Introduction

11.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.11.5 UCB Recent Development

11.12 Teva Pharmaceutical Industries Ltd.

11.12.1 Teva Pharmaceutical Industries Ltd. Company Details

11.12.2 Teva Pharmaceutical Industries Ltd. Business Overview

11.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction

11.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.12.5 Teva Pharmaceutical Industries Ltd. Recent Development

11.13 Vertical Pharmaceuticals, LLC

11.13.1 Vertical Pharmaceuticals, LLC Company Details

11.13.2 Vertical Pharmaceuticals, LLC Business Overview

11.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction

11.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.13.5 Vertical Pharmaceuticals, LLC Recent Development

11.14 ACADIA Pharmaceuticals Inc.

11.14.1 ACADIA Pharmaceuticals Inc. Company Details

11.14.2 ACADIA Pharmaceuticals Inc. Business Overview

11.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction

11.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2020-2025)

11.14.5 ACADIA Pharmaceuticals Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

AbbVie

Mylan Laboratories

Valeant Pharmaceuticals

Novartis

GlaxoSmithKline PLC

Zambon Pharmaceuticals

Pfizer Inc

Hoffmann La Roche

Merck

Orion Pharma

UCB

Teva Pharmaceutical Industries Ltd

Vertical Pharmaceuticals LLC

ACADIA Pharmaceuticals Inc.

List of Tables

Table 1. Global Anti-Parkinson Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Dopaminergic

Table 3. Key Players of Dopamine Agonists

Table 4. Key Players of Enzyme Inhibitors

Table 5. Key Players of Others

Table 6. Global Anti-Parkinson Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Anti-Parkinson Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Anti-Parkinson Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Anti-Parkinson Drugs Market Share by Region (2020-2025)

Table 10. Global Anti-Parkinson Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Anti-Parkinson Drugs Market Share by Region (2026-2031)

Table 12. Anti-Parkinson Drugs Market Trends

Table 13. Anti-Parkinson Drugs Market Drivers

Table 14. Anti-Parkinson Drugs Market Challenges

Table 15. Anti-Parkinson Drugs Market Restraints

Table 16. Global Anti-Parkinson Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Anti-Parkinson Drugs Market Share by Players (2020-2025)

Table 18. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2024)

Table 19. Ranking of Global Top Anti-Parkinson Drugs Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Anti-Parkinson Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Anti-Parkinson Drugs, Headquarters and Area Served

Table 22. Global Key Players of Anti-Parkinson Drugs, Product and Application

Table 23. Global Key Players of Anti-Parkinson Drugs, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Anti-Parkinson Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Anti-Parkinson Drugs Revenue Market Share by Type (2020-2025)

Table 27. Global Anti-Parkinson Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Anti-Parkinson Drugs Revenue Market Share by Type (2026-2031)

Table 29. Global Anti-Parkinson Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Anti-Parkinson Drugs Revenue Market Share by Application (2020-2025)

Table 31. Global Anti-Parkinson Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Anti-Parkinson Drugs Revenue Market Share by Application (2026-2031)

Table 33. North America Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Anti-Parkinson Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Anti-Parkinson Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Anti-Parkinson Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Anti-Parkinson Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Anti-Parkinson Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Anti-Parkinson Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Anti-Parkinson Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 48. AbbVie Company Details

Table 49. AbbVie Business Overview

Table 50. AbbVie Anti-Parkinson Drugs Product

Table 51. AbbVie Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 52. AbbVie Recent Development

Table 53. Mylan Laboratories Company Details

Table 54. Mylan Laboratories Business Overview

Table 55. Mylan Laboratories Anti-Parkinson Drugs Product

Table 56. Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 57. Mylan Laboratories Recent Development

Table 58. Valeant Pharmaceuticals Company Details

Table 59. Valeant Pharmaceuticals Business Overview

Table 60. Valeant Pharmaceuticals Anti-Parkinson Drugs Product

Table 61. Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 62. Valeant Pharmaceuticals Recent Development

Table 63. Novartis Company Details

Table 64. Novartis Business Overview

Table 65. Novartis Anti-Parkinson Drugs Product

Table 66. Novartis Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 67. Novartis Recent Development

Table 68. GlaxoSmithKline Company Details

Table 69. GlaxoSmithKline Business Overview

Table 70. GlaxoSmithKline Anti-Parkinson Drugs Product

Table 71. GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 72. GlaxoSmithKline Recent Development

Table 73. Zambon Pharmaceuticals Company Details

Table 74. Zambon Pharmaceuticals Business Overview

Table 75. Zambon Pharmaceuticals Anti-Parkinson Drugs Product

Table 76. Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 77. Zambon Pharmaceuticals Recent Development

Table 78. Pfizer, Inc. Company Details

Table 79. Pfizer, Inc. Business Overview

Table 80. Pfizer, Inc. Anti-Parkinson Drugs Product

Table 81. Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 82. Pfizer, Inc. Recent Development

Table 83. Hoffmann-La Roche Company Details

Table 84. Hoffmann-La Roche Business Overview

Table 85. Hoffmann-La Roche Anti-Parkinson Drugs Product

Table 86. Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 87. Hoffmann-La Roche Recent Development

Table 88. Merck & Co. Company Details

Table 89. Merck & Co. Business Overview

Table 90. Merck & Co. Anti-Parkinson Drugs Product

Table 91. Merck & Co. Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 92. Merck & Co. Recent Development

Table 93. Orion Pharma Company Details

Table 94. Orion Pharma Business Overview

Table 95. Orion Pharma Anti-Parkinson Drugs Product

Table 96. Orion Pharma Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 97. Orion Pharma Recent Development

Table 98. UCB Company Details

Table 99. UCB Business Overview

Table 100. UCB Anti-Parkinson Drugs Product

Table 101. UCB Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 102. UCB Recent Development

Table 103. Teva Pharmaceutical Industries Ltd. Company Details

Table 104. Teva Pharmaceutical Industries Ltd. Business Overview

Table 105. Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Product

Table 106. Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 107. Teva Pharmaceutical Industries Ltd. Recent Development

Table 108. Vertical Pharmaceuticals, LLC Company Details

Table 109. Vertical Pharmaceuticals, LLC Business Overview

Table 110. Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Product

Table 111. Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 112. Vertical Pharmaceuticals, LLC Recent Development

Table 113. ACADIA Pharmaceuticals Inc. Company Details

Table 114. ACADIA Pharmaceuticals Inc. Business Overview

Table 115. ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Product

Table 116. ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2020-2025) & (US$ Million)

Table 117. ACADIA Pharmaceuticals Inc. Recent Development

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

Table 121. Authors List of This Report

List of Figures

Figure 1. Anti-Parkinson Drugs Picture

Figure 2. Global Anti-Parkinson Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Anti-Parkinson Drugs Market Share by Type: 2024 VS 2031

Figure 4. Dopaminergic Features

Figure 5. Dopamine Agonists Features

Figure 6. Enzyme Inhibitors Features

Figure 7. Others Features

Figure 8. Global Anti-Parkinson Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Anti-Parkinson Drugs Market Share by Application: 2024 VS 2031

Figure 10. Hospital Pharmacy Case Studies

Figure 11. Retail Pharmacy Case Studies

Figure 12. Online Stores Case Studies

Figure 13. Anti-Parkinson Drugs Report Years Considered

Figure 14. Global Anti-Parkinson Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Anti-Parkinson Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Anti-Parkinson Drugs Market Share by Region: 2024 VS 2031

Figure 17. Global Anti-Parkinson Drugs Market Share by Players in 2024

Figure 18. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Anti-Parkinson Drugs Revenue in 2024

Figure 20. North America Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Anti-Parkinson Drugs Market Share by Country (2020-2031)

Figure 22. United States Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Anti-Parkinson Drugs Market Share by Country (2020-2031)

Figure 26. Germany Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Anti-Parkinson Drugs Market Share by Region (2020-2031)

Figure 34. China Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Anti-Parkinson Drugs Market Share by Country (2020-2031)

Figure 42. Mexico Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Anti-Parkinson Drugs Market Share by Country (2020-2031)

Figure 46. Turkey Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Anti-Parkinson Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. AbbVie Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 50. Mylan Laboratories Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 51. Valeant Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 52. Novartis Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 53. GlaxoSmithKline Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 54. Zambon Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 55. Pfizer, Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 56. Hoffmann-La Roche Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 57. Merck & Co. Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 58. Orion Pharma Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 59. UCB Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 60. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 61. Vertical Pharmaceuticals, LLC Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 62. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2020-2025)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Anti Parkinson s Disease Drugs Market Research Report 2024

Global Targeted Drugs for Parkinson s Disease Market Research Report 2024

Global Parkinson s Disease Treatment Market Insights Forecast to 2030

Global Drugs for Central Nervous System Diseases Market Insights Forecast to 2030

Global Parkinson Treatment Drug Market Research Report 2025

Global Leishmaniasis Treatment Market Insights Forecast to 2030

Global Diabetic Neurological Disorder Therapeutic Drug Market Insights Forecast to 2030

Global Parkinsons Disease Drug Market Insights Forecast to 2030

Global Rheumatic Disorders Drug Market Insights Forecast to 2030

Global Alzheimers and Parkinsons Diseases Market Insights Forecast to 2030

Global Parkinson s Disease PD Drugs Market Research Report 2024

Global Gaucher Disease GD Drugs Market Insights Forecast to 2030

Global Antidepressants Drugs Market Insights Forecast to 2030

Global ADHD Medications Market Insights Forecast to 2030

Global Neurodegenerative Disease Market Insights Forecast to 2030

Global Atherosclerosis Drugs Market Insights Forecast to 2030

Global Alzheimer s Disease Therapeutics and Diagnostics Market Insights Forecast to 2030

Global Cold Treatment Drug Market Insights Forecast to 2030

Global Parkinson s Disease Therapeutics Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions